Barbara Ann Karmanos Cancer Institute [clinicaltrials_resource:cf661e67b2a3ff212717e5df0311cd10]
Ira Winer [clinicaltrials_resource:01f12ee0256f87b1446419267267073c]Antonio Pellicer, MDPhD [clinicaltrials_resource:04d4442faff5f7e35e194ccdd801cc11]Maxim Yankelevich [clinicaltrials_resource:06f76d016fd4b9ea2c41a558e873d719]Lawrence Lum, M.D. [clinicaltrials_resource:07523ee149497558a3956fc9ce6e81df]Jordan Maier [clinicaltrials_resource:08d9a703ec31147f406af1b99cf7d7a2]Anthony F. Shields, M.D., Ph.D. [clinicaltrials_resource:09c1f1f5d9fa7f7f9c7c464482197edf]Philip A. Philip, M.D., Ph.D., F.R.C.P [clinicaltrials_resource:0b91e6471b7fd20c7255555442a4c6fe]Paul Swerdlow, MD [clinicaltrials_resource:0cb9ed48757f0ceb0bd550f9e97d6094]Peter J. Littrup, MD [clinicaltrials_resource:0df7a0592ed5735a35930f1b4ab21184]Philip A. Philip, MD, PhD, FRCP [clinicaltrials_resource:0e79681fcce26ddb700a3bb37eb0d1e8]Ulka Vaishampayan [clinicaltrials_resource:0ee9a145ea35f6ad831852d1c54552e6]Maxim Yankelevich [clinicaltrials_resource:11f74bc6af4cb4db2dbd6f93cb862204]Maha Hadi A. Hussain, MD [clinicaltrials_resource:14989ecb0a780355105a6d150eb9fe6b]Abraham Kroon, MD, PhD [clinicaltrials_resource:1526800ff7e961797416facd992a3b32]Maxim Yankelevich [clinicaltrials_resource:20226edbf0293cb1cf1cb6dadc5355cc]Jordan Maier [clinicaltrials_resource:253ba57a84d4d5eefeb69f09fab89480]Esteban Abella, MD [clinicaltrials_resource:2597b266c4b00c3a2ecdc99ae8f23b45]Ulka N. Vaishampayan, MD [clinicaltrials_resource:2c3d2cf6e9e005a59abb4e114ac9f9ef]Andrew E. Sloan, MD [clinicaltrials_resource:2cc7960821f25a79578741234223595a]Zaid Al-Kadhimi, MD [clinicaltrials_resource:2cf20fde1c2baceda8c69fc190808b64]David S. Eilender, MD [clinicaltrials_resource:2db9ce1a1a08b08a0661dfbe15494e89]Lawrence G. Lum, MD, DSc [clinicaltrials_resource:2f9e256b44c4072944012606e69d3442]Ayad M. Al-Katib, MD, FACP [clinicaltrials_resource:30266828ebdca5ff5458704ea2c53c31]Alex Adjei [clinicaltrials_resource:3030474067bbeee8dd68b8365e235940]Neeraj Agarwal, M.D. [clinicaltrials_resource:30e9b109ca5f829f6dd7a63f5b9125a1]Fazlul Sarkar, MD [clinicaltrials_resource:327d495d6686c843416040d639e13cc3]Ho-Sheng Lin, MD [clinicaltrials_resource:3705688a3a90f0e9fca1f9188b9de9a4]Jeffrey A. Zonder, MD [clinicaltrials_resource:3c018f5b7404bcc090e03eff032cb5d6]Shirish Gadgeel [clinicaltrials_resource:3f8cf11828511d229e5249f7edf82b3f]Francis G. LeVeque, DDS [clinicaltrials_resource:406f64ae6c6bf6a850070a44d7f4e0ac]Roy D. Baynes, MD, PhD, FACP [clinicaltrials_resource:43916804275401556c1a39699c13c29a]Maxim Yankelevich [clinicaltrials_resource:44158f6a7dcda466a3b5c62d69d9a9f8]Ira Winer [clinicaltrials_resource:4c0b1c26117f1d2d2112d7217e340537]Frank A. Baciewicz, MD [clinicaltrials_resource:4ccccd11a2476729c0ce4eca3773711a]Anthony F. Shields, MD, PhD [clinicaltrials_resource:4d82df4073e4240bf2cc0a90e2d59bcd]Michael L. Cher, MD [clinicaltrials_resource:4f2684962ea0aacc684b7843a9311740]Peter Littrup [clinicaltrials_resource:508a25ccc4af2502079068e866dc2a68]Novartis Pharmaceuticals [clinicaltrials_resource:52ab2fa5d991f9126acca16edb7e91df]Elisabeth Heath [clinicaltrials_resource:53dcffcab4a110991197d72e158d01d1]Omer Kucuk, MD [clinicaltrials_resource:5b230ab657390e011c782d9703383f2e]
affiliation [clinicaltrials_vocabulary:affiliation]
Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome [clinicaltrials:NCT00002547]Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma [clinicaltrials:NCT00002552]Pyrazoloacridine in Treating Women With Metastatic Breast Cancer [clinicaltrials:NCT00002585]clinicaltrials:NCT00002656Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma [clinicaltrials:NCT00002907]Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [clinicaltrials:NCT00002908]KRN5500 in Treating Patients With Metastatic Solid Tumors [clinicaltrials:NCT00002923]Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome [clinicaltrials:NCT00003171]Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia [clinicaltrials:NCT00003174]Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer [clinicaltrials:NCT00003220]Fenretinide in Treating Patients With Solid Tumors [clinicaltrials:NCT00003250]Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy [clinicaltrials:NCT00003626]Combination Chemotherapy In Treating Patients With Advanced Cancer [clinicaltrials:NCT00003925]Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's Disease [clinicaltrials:NCT00003936]Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery [clinicaltrials:NCT00004003]Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma [clinicaltrials:NCT00004022]Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma [clinicaltrials:NCT00004024]Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer [clinicaltrials:NCT00004144]Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer [clinicaltrials:NCT00005027]Chemotherapy in Treating Patients With Advanced Kidney Cancer [clinicaltrials:NCT00011973]Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer [clinicaltrials:NCT00014573]Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors [clinicaltrials:NCT00016185]clinicaltrials:NCT00020722clinicaltrials:NCT00027807XK469 in Treating Patients With Advanced Solid Tumors [clinicaltrials:NCT00028548]clinicaltrials:NCT00030407clinicaltrials:NCT00030420Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors [clinicaltrials:NCT00052403]Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia [clinicaltrials:NCT00056004]Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia [clinicaltrials:NCT00066326]clinicaltrials:NCT00068653clinicaltrials:NCT00078923clinicaltrials:NCT00217581PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma [clinicaltrials:NCT00238329]Isoflavones and Radiation Therapy in Treating Patients With Localized Prostate Cancer [clinicaltrials:NCT00243048]clinicaltrials:NCT00244933clinicaltrials:NCT00244946clinicaltrials:NCT00248482clinicaltrials:NCT00248560Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer [clinicaltrials:NCT00258232]
collaborator [clinicaltrials_vocabulary:collaborator]
Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome [clinicaltrials:NCT00002547]Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma [clinicaltrials:NCT00002552]Pyrazoloacridine in Treating Women With Metastatic Breast Cancer [clinicaltrials:NCT00002585]clinicaltrials:NCT00002656Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma [clinicaltrials:NCT00002907]Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [clinicaltrials:NCT00002908]KRN5500 in Treating Patients With Metastatic Solid Tumors [clinicaltrials:NCT00002923]Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome [clinicaltrials:NCT00003171]Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia [clinicaltrials:NCT00003174]Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer [clinicaltrials:NCT00003220]Fenretinide in Treating Patients With Solid Tumors [clinicaltrials:NCT00003250]Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy [clinicaltrials:NCT00003626]Combination Chemotherapy In Treating Patients With Advanced Cancer [clinicaltrials:NCT00003925]Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's Disease [clinicaltrials:NCT00003936]Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery [clinicaltrials:NCT00004003]Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma [clinicaltrials:NCT00004022]Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma [clinicaltrials:NCT00004024]Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer [clinicaltrials:NCT00004144]Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer [clinicaltrials:NCT00005027]Chemotherapy in Treating Patients With Advanced Kidney Cancer [clinicaltrials:NCT00011973]Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer [clinicaltrials:NCT00014573]Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors [clinicaltrials:NCT00016185]clinicaltrials:NCT00020722clinicaltrials:NCT00027807XK469 in Treating Patients With Advanced Solid Tumors [clinicaltrials:NCT00028548]clinicaltrials:NCT00030407clinicaltrials:NCT00030420Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors [clinicaltrials:NCT00052403]Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia [clinicaltrials:NCT00056004]Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia [clinicaltrials:NCT00066326]clinicaltrials:NCT00068653clinicaltrials:NCT00078923clinicaltrials:NCT00217581PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma [clinicaltrials:NCT00238329]Isoflavones and Radiation Therapy in Treating Patients With Localized Prostate Cancer [clinicaltrials:NCT00243048]clinicaltrials:NCT00244933clinicaltrials:NCT00244946clinicaltrials:NCT00248482clinicaltrials:NCT00248560Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer [clinicaltrials:NCT00258232]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
organization [clinicaltrials_vocabulary:organization]
Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome [clinicaltrials:NCT00002547]Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma [clinicaltrials:NCT00002552]Pyrazoloacridine in Treating Women With Metastatic Breast Cancer [clinicaltrials:NCT00002585]clinicaltrials:NCT00002656Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma [clinicaltrials:NCT00002907]Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [clinicaltrials:NCT00002908]KRN5500 in Treating Patients With Metastatic Solid Tumors [clinicaltrials:NCT00002923]Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome [clinicaltrials:NCT00003171]Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia [clinicaltrials:NCT00003174]Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer [clinicaltrials:NCT00003220]Fenretinide in Treating Patients With Solid Tumors [clinicaltrials:NCT00003250]Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy [clinicaltrials:NCT00003626]Combination Chemotherapy In Treating Patients With Advanced Cancer [clinicaltrials:NCT00003925]Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's Disease [clinicaltrials:NCT00003936]Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery [clinicaltrials:NCT00004003]Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma [clinicaltrials:NCT00004022]Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma [clinicaltrials:NCT00004024]Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer [clinicaltrials:NCT00004144]Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer [clinicaltrials:NCT00005027]Chemotherapy in Treating Patients With Advanced Kidney Cancer [clinicaltrials:NCT00011973]Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer [clinicaltrials:NCT00014573]Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors [clinicaltrials:NCT00016185]clinicaltrials:NCT00020722clinicaltrials:NCT00027807XK469 in Treating Patients With Advanced Solid Tumors [clinicaltrials:NCT00028548]clinicaltrials:NCT00030407clinicaltrials:NCT00030420Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors [clinicaltrials:NCT00052403]Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia [clinicaltrials:NCT00056004]Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia [clinicaltrials:NCT00066326]clinicaltrials:NCT00068653clinicaltrials:NCT00078923clinicaltrials:NCT00217581clinicaltrials:NCT00227721PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma [clinicaltrials:NCT00238329]Isoflavones and Radiation Therapy in Treating Patients With Localized Prostate Cancer [clinicaltrials:NCT00243048]clinicaltrials:NCT00244933clinicaltrials:NCT00244946clinicaltrials:NCT00248482clinicaltrials:NCT00248560
source [clinicaltrials_vocabulary:source]
Barbara Ann Karmanos Cancer Institute [clinicaltrials_resource:cf661e67b2a3ff212717e5df0311cd10]
Bio2RDF identifier
cf661e67b2a3ff212717e5df0311cd10
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:cf661e67b2a3ff212717e5df0311cd10
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:cf661e67b2a3ff212717e5df0311cd10
title
Barbara Ann Karmanos Cancer Institute
@en
type
label
Barbara Ann Karmanos Cancer In ...... 61e67b2a3ff212717e5df0311cd10]
@en